Presidio Medical, Inc.

Presidio Medical, Inc. is a clinical-stage medical technology company based in San Mateo, California, founded in 2017. The company focuses on developing an innovative neuromodulation platform known as Ultra Low Frequency (ULF™) Neuromodulation, specifically targeting chronic nociceptive pain, including chronic low back pain. This condition often lacks effective treatment options, making Presidio Medical's work particularly significant. The core technology utilizes ultra-low frequency biphasic electrical signals delivered through leads implanted in the epidural space, aiming to block nerve conduction without causing tissue damage. This method has shown promising results in clinical trials, with pain relief improvements reported up to 90% in patients with chronic leg and back pain. Presidio Medical is currently conducting pivotal clinical trials, including the FULFILL Study, and has secured $72 million in Series C funding to enhance its operations and advance its clinical studies. The company serves patients suffering from chronic nociceptive pain and healthcare providers looking for advanced solutions in pain management. Presidio Medical is dedicated to transforming treatment approaches and improving the quality of life for those affected by chronic pain.

• Employees 60
• Founded 2017
• Annual Revenue $2322000
• Total Funding $102000000